Oncolytics Biotech Inc. announced the expansion of enrollment for the anal cancer cohort of the GOBLET study evaluating pelareorep in combination with atezolizumab (Tecentriq®) in patients with second-line or later unresectable squamous cell carcinoma of the anal canal (SCCA). The study was expanded based on positive data from Stage 1 of the study, presented at the 2nd International Multidisciplinary Anal Cancer Conference (IMACC) in November 2023.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.53 CAD | -1.29% | -3.77% | -14.53% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.53% | 85.86M | |
+34.48% | 50.85B | |
+0.51% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+10.97% | 26.11B | |
-21.60% | 19.13B | |
+8.32% | 13.05B | |
+27.13% | 12.16B | |
+24.47% | 12.08B |
- Stock Market
- Equities
- ONC Stock
- News Oncolytics Biotech Inc.
- Oncolytics Biotech Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort